Caution is advised for patients with a history of pancreatitis, gallbladder disease, kidney disease, diabetic retinopathy, or gastrointestinal motility disorders
Tuy nhin, liu y c phi l gii php hon ho cho ln da trng sng, mn mng nh mun
doi: 10.1016/j.exer.2015.02.007 94 McKinnonBDLukowskiSWMortlockSCrawfordJAtluriSSubramaniamSet al
This article explores early warning Read More Incretin Therapy Selection in High-Risk Patients: What New Outcomes Data Suggest May 4, 2026 Articles, Cardiology, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 876 views Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope
Mounjaro is approved to treat type 2 diabetes and Zepbound is approved for weight loss
Current litigation alleges that Eli Lilly used an unconventional launch strategy by focusing on payers rather than targeting physicians directly and that they used sales representatives to emphasize Trulicitys benefits to insurance providers and payers
